Research indicates that for the HER2-+, Michigan Cancer Foundation (MCF-7) and Sloan-Kettering breast cancer (SKBR-3) cells, the DOX-loaded liposomal formulations had a lower half-maximal inhibitory concentration (IC50) than the systemically intravenous injected DOX, and are more effective in killing cancer cells [29]. This evidence concerns the gene ERBB2 and breast carcinoma.